Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

BACKGROUND: The use of nivolumab or irinotecan as the third-line treatment for patients with advanced gastric cancer (AGC) remains controversial. METHODS: This study analyzed patients with AGC treated with nivolumab or irinotecan (nivolumab group or irinotecan group, respectively) from May 2016 to A...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Takahiro, Kawazoe, Akihito, Sasaki, Akinori, Mishima, Saori, Kentaro, Sawada, Nakamura, Yoshiaki, Kotani, Daisuke, Kuboki, Yasutoshi, Taniguchi, Hiroya, Kojima, Takashi, Doi, Toshihiko, Yoshino, Takayuki, Kuwata, Takeshi, Ishii, Genichiro, Shitara, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370559/
https://www.ncbi.nlm.nih.gov/pubmed/32733607
http://dx.doi.org/10.1177/1758835920942377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370559/
https://www.ncbi.nlm.nih.gov/pubmed/32733607
http://dx.doi.org/10.1177/1758835920942377

Ejemplares similares